KaloBios to Present at Disruptive Growth & Healthcare Conference
BRISBANE, CA / ACCESSWIRE / February 13, 2017 / KaloBios Pharmaceuticals, Inc. (OTC PINK: KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present a company overview at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16, 2017 at 1:15 p.m. EST.
The conference will be held February 15-16, 2017 in New York City. A live webcast of the presentation will be available at http://www.investorcalendar.com/event/11193.
For more information on the conference, please visit www.disruptnyc.com.
News Compliments of Accesswire.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole, for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers, such as CMML and potentially JMML. For more information, visit www.kalobios.com.
Forward-Looking Statements
This release contains forward-looking statements that are intended to be subject to protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements related to expectations regarding the regulatory pathway for benznidazole and the Company's other product candidates, including the possible eligibility of such products for receipt of a priority review voucher; the Company's opportunity to benefit from the application of our Responsible Pricing Model; and expectations for the Company's future financial position. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, our lack of profitability and the need for additional capital to operate our business as a going concern; the uncertainties inherent in the development and launch of any new pharmaceutical product; our ability to successfully and timely complete clinical trials for our drug candidates in clinical development; our ability to obtain the necessary U.S. and international regulatory approvals for our drug candidates and to qualify for or benefit from various regulatory incentives; the scope and validity of intellectual property and other competitive protection for our drug candidates; our ability to identify, in-license and acquire additional product candidates or to form partnerships for the sale, licensing, collaborative development, or marketing of our existing product candidates; our ability to maintain or engage third-party manufacturers to manufacture, supply, store, and distribute supplies of our drug candidates for our clinical trials; and the success of any product; and the various risks and uncertainties described in the "Risk Factors" and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.
CONTACT:
Investors:
Mike Cole
O: 949-259-4988
C: 949-444-1341
mike.cole@mzgroup.us
Media:
Lisa Guiterman
O: 301-217-9353
C: 202-330-3431
media@kalobios.com
SOURCE: KaloBios Pharmaceuticals, Inc.
